Destiny Pharma Share Discussion Threads

[raleigh43] 25/4/2024 08:11

This share was good for me. Bought low sold high by chance. A reminder that these days you have to take profits when they arise and not fall in love with a share or ‘the story’

[purple11] 25/4/2024 07:57

Daily MAIL tipping these@50p

they dont get em all right!

[idomeneo] 25/4/2024 07:39

No licensing deal for XF-73 nasal: Despite engaging with potential partners and receiving positive feedback, Destiny Pharma has not been able to secure a licensing deal for XF-73 nasal that they believe provides fair value to the company and its shareholders. This lack of a deal could be seen as a setback by investors.
Uncertainty about the future of XF-73 nasal: The company is now undertaking a review of strategic options to determine how best to advance XF-73 nasal through Phase 3 clinical trials. This review introduces uncertainty about the future development path of the product, which could make investors nervous.
Potential need for additional financing: As part of the strategic review, Destiny Pharma is considering the possibility of securing finance to enable it to conduct the Phase 3 clinical studies itself. This suggests that the company may need to raise additional funds, which could dilute existing shareholders or be seen as a risk if the financing is not secured.
Perception of the commercial potential of antibiotics: The announcement mentions that potential partners have expressed concerns about the prevailing perceptions of the commercial potential of antibiotics. This could indicate a broader market sentiment that may be affecting the valuation of companies working in this space.

While the announcement also highlights some positive developments, such as the partnership with Sebela Pharmaceuticals and the potential cost savings from a new clinical trial design for XF-73 nasal, the overall tone of the update seems to have introduced more uncertainty and potential challenges, which could explain the negative market reaction.

[adorling] 25/4/2024 07:18

XF73-Nasal - the bubble has well and truly burst. Pharmas/Biotech CO’s doing due diligence over past 8 months obviously do not see a commercial return vs Phase 3 trial costs and upfront payment and royalty’s. Not good as clinical results have been outstanding to date. Management called it wrong and Tovey has that on his record now.

[the codger] 25/4/2024 07:17

It's unfortunate but that's the gamble

[s34icknote] 25/4/2024 07:15

Another junk status pharma to go with dddd and the rest ! Avoid pharma they're hazardous to your health ! More trials more money !

[john henry] 25/4/2024 07:03

unbelievably they hadnt nailed the cost of the phase 3 trial no wonder no JV was forecoming.

Out at 17p for a loss.

[bones698] 25/4/2024 06:57

What they think the company is worth and what the market thinks are probably very wide apart however anyone looking to acquire wil gonoff the current mkt cap and not what the current ceo thinks. Hence no deals or offers imo. If management were any good they would have raised with the share price higher months ago. Now it's a big problem they face and shareholders will pay the price
Sub 15p today maybe 13p by eod

[banshee] 25/4/2024 06:39

"Currently, the review is not actively considering an offer for the company." In other words they are open to offers.

Suprised they have yet to quantify the size of the market for diabetic foot ulcers for example. Their best option for XF-73 nasal is to shelf it if the new trial design does not attract partners imo. All very predictable, given the FDA requirement of a trial for every indication,they should have developed the dermal product first imo.

Sebela confirm rerun of p2 required for M3 also as predicted, which means they can get the regulatory paperwork done early, so p3 will be ready to start circa h2 2025/h1 2026, assuming all goes well. Still incomprehensible why Destiny did not reformulate post P3.

[mikeh30] 25/4/2024 06:23

Hmmmm. Pharma Cos in the data room have obviously seen something they don't like. Issue is now the glimmering hope of a deal and an upfront cash payment to stave off a fundraising is gone.Now it's damage control for the fundraise Heading sub 10p unfortunately

[waterloo01] 25/4/2024 06:21

Gulp indeed.

[john henry] 25/4/2024 06:21

Cash run remains the same q1 2025, however everything pushed back many many months.

[john henry] 25/4/2024 06:21

Will be interesting to hear what Tovey has to say on IMC

[wh1spa] 23/4/2024 14:56

If someone were to buy a 25% stake here on the open market , what affect would this have on the share price So if a fundraising is in the offing I'm hoping for a premium to today's price.

[john henry] 22/4/2024 07:44

Some decent churn these past few trading days

[john henry] 22/4/2024 07:24

Some decent buying these past few trading days

[simonlevert] 21/4/2024 06:01

IIG absolutely could look at a stake in DEST given their track record. If the public market doesn’t value companies like this then private equity and VC’s will hxxps://iigplc.com/board-and-investment-committee/

[wh1spa] 16/4/2024 18:00

May explain why Shore became sole broker and Nomad here and Cavendish became IIG's at a similar time.

[wh1spa] 16/4/2024 17:54

Could Sir Nigel's IIG take a significant stake in DEST - Chairman of both so perhaps it's a non starter or at least would somehow have to be at arms length re valuations etc.

[wh1spa] 16/4/2024 06:14

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600368/Buying more today..... (even with a fundraising these are still absurdly cheap)

[bones698] 15/4/2024 16:00

Jh making up numbers trying not to look as stupid as he really is again. You have been caught out yet again idiot